226 related articles for article (PubMed ID: 19037839)
41. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas.
Kasper B; Hohenberger P
Future Oncol; 2011 Dec; 7(12):1373-83. PubMed ID: 22112314
[TBL] [Abstract][Full Text] [Related]
42. Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.
Pal SK; Hossain DM; Zhang Q; Frankel PH; Jones JO; Carmichael C; Ruel C; Lau C; Kortylewski M
J Urol; 2015 Apr; 193(4):1114-21. PubMed ID: 25286010
[TBL] [Abstract][Full Text] [Related]
43. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
Yafai Y; Yang XM; Niemeyer M; Nishiwaki A; Lange J; Wiedemann P; King AG; Yasukawa T; Eichler W
Eur J Pharmacol; 2011 Sep; 666(1-3):12-8. PubMed ID: 21620822
[TBL] [Abstract][Full Text] [Related]
44. Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial.
Maughan BL; Pal SK; Gill D; Boucher K; Martin C; Salgia M; Nussenzveig R; Liu T; Hawks JL; Batten J; Nachaegari G; Stephenson R; Lowrance W; Jones J; Dechet C; Agarwal N
Oncologist; 2018 Dec; 23(12):1413-e151. PubMed ID: 30575560
[TBL] [Abstract][Full Text] [Related]
45. Effect of pazopanib on tumor microenvironment and liposome delivery.
Tailor TD; Hanna G; Yarmolenko PS; Dreher MR; Betof AS; Nixon AB; Spasojevic I; Dewhirst MW
Mol Cancer Ther; 2010 Jun; 9(6):1798-808. PubMed ID: 20515941
[TBL] [Abstract][Full Text] [Related]
46. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors.
Minkovsky N; Berezov A
Curr Opin Investig Drugs; 2008 Dec; 9(12):1336-46. PubMed ID: 19037840
[TBL] [Abstract][Full Text] [Related]
47. Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma.
Bonate PL; Suttle AB
Cancer Chemother Pharmacol; 2013 Jul; 72(1):231-40. PubMed ID: 23715625
[TBL] [Abstract][Full Text] [Related]
48. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
49. Pazopanib in the treatment of soft tissue sarcoma.
Schöffski P
Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
[TBL] [Abstract][Full Text] [Related]
50. Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
Glaser KB; Li J; Marcotte PA; Magoc TJ; Guo J; Reuter DR; Tapang P; Wei RQ; Pease LJ; Bui MH; Chen Z; Frey RR; Johnson EF; Osterling DJ; Olson AM; Bouska JJ; Luo Y; Curtin ML; Donawho CK; Michaelides MR; Tse C; Davidsen SK; Albert DH
J Pharmacol Exp Ther; 2012 Dec; 343(3):617-27. PubMed ID: 22935731
[TBL] [Abstract][Full Text] [Related]
51. Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).
O'Brien ME; Gaafar R; Hasan B; Menis J; Cufer T; Popat S; Woll PJ; Surmont V; Georgoulias V; Montes A; Blackhall F; Hennig I; Schmid-Bindert G; Baas P;
Eur J Cancer; 2015 Aug; 51(12):1511-28. PubMed ID: 26074395
[TBL] [Abstract][Full Text] [Related]
52. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
53. Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709.
Siemeister G; Luecking U; Wagner C; Detjen K; Mc Coy C; Bosslet K
Biomed Pharmacother; 2006 Jul; 60(6):269-72. PubMed ID: 16887322
[TBL] [Abstract][Full Text] [Related]
54. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
55. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
[TBL] [Abstract][Full Text] [Related]
56. High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors.
Chauvin C; Leruste A; Tauziede-Espariat A; Andrianteranagna M; Surdez D; Lescure A; Han ZY; Anthony E; Richer W; Baulande S; Bohec M; Zaidi S; Aynaud MM; Maillot L; Masliah-Planchon J; Cairo S; Roman-Roman S; Delattre O; Del Nery E; Bourdeaut F
Cell Rep; 2017 Nov; 21(7):1737-1745. PubMed ID: 29141209
[TBL] [Abstract][Full Text] [Related]
57. The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.
Chellappan DK; Chellian J; Ng ZY; Sim YJ; Theng CW; Ling J; Wong M; Foo JH; Yang GJ; Hang LY; Nathan S; Singh Y; Gupta G
Biomed Pharmacother; 2017 Dec; 96():768-781. PubMed ID: 29054093
[TBL] [Abstract][Full Text] [Related]
58. Initial testing of the multitargeted kinase inhibitor pazopanib by the Pediatric Preclinical Testing Program.
Keir ST; Morton CL; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2012 Sep; 59(3):586-8. PubMed ID: 22190407
[TBL] [Abstract][Full Text] [Related]
59. Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells.
Li Y; Yang X; Su LJ; Flaig TW
Urology; 2011 Jul; 78(1):233.e7-13. PubMed ID: 21529900
[TBL] [Abstract][Full Text] [Related]
60. Targeted therapies: Pazopanib: carving a niche in a crowded therapeutic landscape.
Pal SK; Figlin RA
Nat Rev Clin Oncol; 2010 Jul; 7(7):362-3. PubMed ID: 20592710
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
